Breaking News, Financial News

Financial Report: Alkermes

Revenues up 14% in the quarter

Alkermes

3Q Revenues: $154.5 million (+14%)

3Q Earnings: $18.1 million (+11%)

YTD Revenues: $432.9 million (+5%)

YTD Earnings: $17.6 million (-20%)

Comments: Manufacturing and royalty revenues in the quarter were $132.7 million, up 12%, driven by the atypical antipsychotic franchise, up 36% to $71.2 million. Product sales were $20.6 million, up 29% driven by and VIVITROL, with sales up 30% to $20.6 million. R&D revenues were $1.2 million, down 31%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters